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Introduction
The objective of tissue engineering is to create or recreate living
body parts or organs that will fully integrate with the recipient’s
body. The advent of tissue engineering as a new field of research
with a high potential towards the clinical care of patients from
bench to bedside has involved numerous different scientists in
various fields of cellular and molecular medicine, material
research, engineering, physics, chemistry, computational research
and allied disciplines [1–5]. Due to a potentially enormous impact
on the health of our society – that is as a whole continuously
becoming older – tissue-engineered solutions to circumvent natural
degenerative processes have become of great interest. They may
aid to maintain a high quality of life in the elderly. This issue has
been widely acknowledged, but has created numerous debates
also. Many of the techniques applied in research and in practical
applications of nowadays tissue engineering approaches [3] with
direct or indirect relation to the care of human beings seem to be
straight forward and do not offer a sufficient potential for ethical
debates [6–8].
Nevertheless, innovative medical research and new technolo-
gies always raise ethical and policy concerns. In biomedical
research, these issues include the ethical conduct of basic and
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clinical research as well as the equitable distribution of new
 therapies [7]. While questions of intellectual property have been
widely published in this context, there is limited literature on
ethics in cellular and molecular medicine and for the field of tissue
engineering [6, 9, 10].
With respect to the ethics of tissue engineering, Derksen and
Horstman [11] have suggested that one can roughly distinguish
two perspectives. On the one hand, this technology could be
 considered morally good because tissue engineering is ‘copying
nature’. On the other hand, tissue engineering could be considered
morally dangerous because it defies nature: bodies constructed in
the laboratory are seen as unnatural. The tremendous public attrac-
tion that the implantation of cultured chondrocytes in the form of a
human ear cartilage (which was implanted under the skin of a nude
mouse and that was eventually called auriculosaurus [1]) gained
rapidly all over the world is a vivid testimony to the perception of
people when confronted with such spectacular and obvious
research efforts. Based on the discussion of the engineering of
heart valves, authors have proposed that the ethics of tissue engi-
neering should be framed not in terms of ‘natural’ or ‘unnatural’ but
in terms of ‘good embodied life’ and ‘lived integrity’ [11].
Historical aspects
While research with stem cells from the very beginning has
evoked many controversial debates worldwide not only within the
recent years (especially when those cells are derived from
embryos), there is comparatively little public debate on ethical
issues in cellular and molecular research, when it is not directly
correlated to clinical applications.
A survey of the literature reveals that the term ‘ethics’ in cellular
and molecular medicine is not covered in a database such as
PubMed, while the term ethics and cellular medicine offers 608
papers published between 1967 and 2008. Decades ago, early
papers such as Vogels report on: ‘Can we count on the possibility
of manipulation in the field of human genetics? May we and are
we permitted to breed people?’ [12] or Hirschhorn’s comment on
‘re-doing man’ [13] were discussing the principle question and the
fear of any manipulation of the human genetic information at all.
At that time even reproductive medicine was in its childhood as
Ramsey’s considerations on the medical ethics of in vitro fertiliza-
tion show [14, 15]. However, it has to be remembered that at the
same time the first successful clinical heart transplantation was
made public in 1967. The public confusion of transplanting organs
from one human being into another – especially the human heart
– was considerable. It is widely recognized that despite better
knowing about the function of the brain even nowadays feelings
are literally more associated with the heart than the brain. The
famous quotation of Antoine De Saint Exupery ‘It is only with 
the heart that one can see rightly; what is essential is invisible to the
eye’ may serve as a vivid example of this phenomenon. Looking
back into this field of scientific publication nowadays such
 questions seem to have been more or less answered over the
time, although it is clear that they cannot be definitely solved for
every opinion and for all times.
For instance, the field of in vitro fertilization to overcome
human infertility has become a clinical routine worldwide and is
currently being financed by many social security systems in devel-
oped countries.
Genetic manipulation of the human genome seems nothing
spectacular today. The human genome has been decoded in many
aspects and DNA fingerprint tests are popular practice in many
fields of our daily life. This demonstrates that parallel to any
progress in cellular and molecular research the debates also are
subject to changing perceptions over time. Issues that have been
extremely controversial decades ago have become less critical in
the public perception today and new challenges arise with the
ever-progressing efforts in cellular and molecular research.
Ethically of course the acclimatization to habits that have become
daily practice does not mean that they are ethically unobjection-
able by themselves. However, an ethical reflection should not be
addicted to fashions and should keep in thinking critically.
Nevertheless, due to the translational character of cellular and
molecular medicine [16–19] many critical questions can arise
from this field of research that may pose ethical problems.
Stem cell research in cellular and
molecular medicine and tissue 
engineering
It is always difficult to estimate the true benefits to individuals and
to society that are gained by the introduction of new drugs or
medical technologies. As an example it may be recognized that the
introduction of antibiotics and vaccines has enormously increased
our life spans and improved the health conditions of people all
over the world. Nevertheless still major illnesses such as cancer,
diabetes mellitus, Alzheimer’s disease, heart disease are ongoing
and challenging conditions, which desire continuous research on
a cellular and molecular basis. Research in human developmental
biology has led to the discovery of human stem cells that have
been described for many decades and that have been subject to
multiple investigations. Human stem cells are precursor cells that
can give rise to multiple tissue types, including embryonic stem
(ES) cells, embryonic germ (EG) cells, and adult stem cells. The
discovery of techniques for the in vitro culture of stem cells has
provided unprecedented opportunities for studying and
 understanding more about human biology [20]. In human beings,
transplants of haematopoietic stem cells following chemothera-
peutic treatments for cancer, for example, have been routinely
administered for many years now.
It has been proposed by scientific communities that persons
considering donating their excess embryos for research purposes
should be afforded the highest standards of protection for the
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informed consent and voluntariness of their decision [21]. But if
the human embryo is seen as a human being – and there are a lot
of reasons to do this – there remains the question why medicine
does not prevent supernumary embryos at all from the ethicist’s
standpoint. In view of the moral concerns surrounding the uses of
embryonic and foetal tissue voiced by a segment of the American
population, it has been proposed by the AAAS (American
Association for the Advancement of Science, Science magazine)
that strengthening federally and privately funded research into
alternative sources and/or methods for the derivation of stem
cells, including further initiatives on adult stem cells, should be
encouraged [21]. According to their statements human stem cell
research can be conducted in a fully ethical manner, but it is con-
sidered to be true that the extraction of embryonic stem cells from
the inner mass of blastocysts raises ethical questions for all those
who consider the intentional loss of embryonic life by intentional
means to be morally wrong. Also, the derivation of embryonic
germ cells from the gonadal tissue of aborted foetuses is problem-
atic for those who oppose abortion [21]. From an ethical point of
view there are enough objections at the moment to the process of
deriving stem cells to consider AAAS recommending against its
public funding.
In contrast, adult stem cell research is more broadly acceptable
to the population. Generally there seems to be no discussion in the
media about the so-called adult stem cells, since the potential 
benefit appears to be very high and the utilization of the patient’s
own cells poses no serious ethical conflict.
Although it is impossible to predict the potential outcome,
momentarily worldwide many experiments carried out that aim
towards the determination of the mechanisms underlying the con-
version of a single, undifferentiated cell into the different cells
comprising the tissues and organs and of the human body. A high
potential of therapeutic effects has been claimed for this field of
research, but is still not sufficiently understood or proven. Given
the widely unsolved ethical, legal, religious and policy questions,
the potential use of stem cells to generate replacement human
 tissues and, perhaps, whole human organs, remains a subject of
ongoing public debate. For the majority of problems arising from
embryonal stem cell research, we want to refer to the pertinent
 literature that is ample and multidimensional [21–27].
There is already preliminary existing evidence from animal
studies that stem cells could potentially differentiate into cells of
choice, and it is hoped that these cells then would act properly in
their transplanted environment. Further, somewhat cruder experi-
ments (e.g. the transplantation of foetal tissue into the brains of
Parkinson’s patients) could indicate that the expectation that stem
cell therapies could possibly provide robust treatments for many
human diseases may be a reasonable one, although this has not
been definitely proven today. It is only through controlled scientific
research that the true promise will be understood.
Recent publications on the re-programming of adult cells into
embryonal-like cells (gPS, “germline derived pluripotent stem
cells”) that behave similar to stem cells [28] may well bridge the
gap between current controversial stand points. The different
ways to reprogram adult cells might offer the possibility to
 produce customized stem cells with the genetic material of the
individual patient [27]. This method would not need the harvest of
stem cells from embryos that then necessarily have to be
destroyed – an act that is forbidden by law in many countries,
such as Germany for instance.
For the moment, in tissue engineering the application of embry-
onic stem cells is not a commonly accepted practice, while human
adult stem cells are the object of frequent investigations [29, 30].
Ethical aspects of mixing human 
and animal tissues
Many experiments in various fields of research in cellular and
molecular medicine are performed worldwide on a daily routine
without a thorough discussion of ethical implications. In tissue
engineering, it is common practice to seed human cells on bio-
materials. Cultured or non-cultured human cells are frequently
seeded onto experimental animals [4, 31–34]. Ethically this
 creates a combined human-animal being, also called chimera.
Such chimeras are commonly perceived as individuals, organs,
or parts of an organism consisting of tissues of diverse genetic
constitution [35]. However, it remains controversial how much
diverse genetic constitution is needed to be allowed to call it
chimera. The question has been brought up by the ethical com-
mittee of first author’s former University how it has to be consid-
ered if chimeric animals with incorporated human cells are still
alive and subject to experimental studies while the original cell
donor may have deceased due to any reason. Although this
question seems to be artificial there is no clear answer how such
a chimera has to be considered, since it carries tissues or stromal
cells from a former human being and may potentially reproduce
itself and theoretically propagate the parts of the initial cell dona-
tor. In the current literature, this issue has not been addressed
so far [36].
With regard to tissue engineering such models have been and
are used frequently for experimental purposes and have been
reviewed by numerous ethical committees to be unproblematic.
This holds true as long as confidentiality and patient privacy is
secured when working with tissues or cells in such models and
ensuring appropriate use of the material for scientific reasons only.
If stem cells are applied in this way, a plethora of ethical
 questions arise immediately. Karpowicz et al. [22] addressed the
question if it is ethical to transplant human stem cells into  
non-human embryos. They postulated that in the future human or
non-human stem cell chimeras will be increasingly applied to
study human cells in developing non-human animals. Such experi -
ments raise a number of issues that may create further controversy
in the stem cell field. These authors tried to outline the scientific
value and ethical ramifications of such studies. In addition, they
try to give suggestions how such experiments may be conducted
ethically. It is proposed that the transplantation of human stem
cells into prenatal non-human animals would allow researchers to
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study human cell development without directly using human
embryos. Intrinsic value and animal integrity are two key concepts
in the debate on the ethics of the genetic engineering of laboratory
animals. These concepts have, on the one hand, a theoretical
 origin and are, on the other hand, based on the moral beliefs of
people not directly involved in the genetic modification of animals
[35]. In a study comparing the moral experiences and opinions of
people directly involved in the creation or use of transgenic laboratory
animals to people not directly involved in the genetic modification
of animals it has been strongly suggested that these concepts
would not have to be adjusted or extended in the light of the moral
experiences and opinions from practice [35]. Nevertheless from
the ethicist’s point of view it remains a question whether such
chimeric organisms have to be created at all. Even the aim to
 create chimeras could theoretically be seen as an ethical assault.
In order to regenerate dysfunctional human tissues, the obser-
vation of large-scale human cell actions in comparative animal
models is deemed necessary to advance future research. This may
help to investigate human stem cell plasticity. Because embryonic
stem cell transplants have been reported to form tumours in post-
natal rats [24], researchers have successfully begun to assay
human embryonic stem cell function using prenatal chimeras
[37]. As an example, retinal stem cells (RSC) found in the adult
mammalian eye [38] form an adult somatic cell population that
represents a potentially valuable therapeutic tool. RSC transplants
are believed to eventually restore sight, and perhaps treat other-
wise intractable diseases, such as macular degeneration and
retinitis pigmentosa. Understanding the specification of retinal fate
during human development, from embryonic cell to early neuroec-
toderm and later retinal lineages, is useful and necessary before
replacing large areas of the human eye becomes possible [22, 23].
According to Karpowicz et al. [22] for molecular biologists,
chimeric DNA refers to sequences derived from two sources and
combined into one; for cell biologists, there are nucleocytoplasmic
hybrids involving somatic cell nuclear transfers (cloning) within or
between species; for embryologists, chimeras are prenatal combi-
nations of cells derived from different zygotes, either intraspecies
or interspecies; for geneticists, there are interspecies genetic
hybrids such as the mule; and finally, there are interspecies
xenografts of tissue into postnatal hosts. When we use the term
‘chimera’ here, we mean transplants of human stem cells into pre-
natal non-human animals, although more broadly speaking, any of
the above combinations can use this analysis [22, 23].
It has been formulated that two hypothetical human/non-human
RSC chimera experiments could be undertaken: (i ) transplants of
adult human RSCs into early embryonic mice at the blastocyst
stage, or (ii ) transplants of adult human RSCs into the eye and
brain of foetal monkeys. The first of these would be a preanatomic
chimera assay, a test of whether human cells can participate in the
morphogenesis of non-retinal mouse tissues. The second would be
a late chimera assay, a restricted and postanatomic analysis of
human RSC contributions to preformed tissue types [22]. These
authors have referred to the Aristotelian teleological philosophy,
which maintains that all living things have an inner tendency to
reach their appropriate ends or goals, and that their biological
functions enable them to achieve this. Contemporary proponents
of this approach argue that although the proper ends of humans
may differ radically from that of mice or monkeys, the intentional
alignment of each with their respective ends is a moral good.
According to this view, it would be wrong to tamper with nature in
ways that prevent living beings from achieving their natural ends or
pursuing their natural way of flourishing [39, 40]. If the merger of
human and non-human tissues within chimeras frustrates the ends
of the beings involved, it would be unnatural and therefore wrong.
Interestingly it can also be objected that, in principle, teleologi-
cal guidance may also leave us to speculate endlessly about the
‘natural’ purposes of virtually all living things. On the other hand,
it can offer only few clues as to what decisions are right [22]. Thus
purely teleological arguments do not give a clear-cut answer to the
question if it is ethically right to prohibit or to support the making
of chimeras as ethically acceptable with any assurance.
Accordingly, there has been reasonable dispute in the past
about limits of medical actions when we do interfere with the
 dysfunctioning human organism by surgery, medical interventions
and transplantations for instance. Therefore, it cannot be generally
regarded to be wrong to intervene into these functions or keep
them from reaching certain ends. The context in which such inter-
ventions are carried out, not just the biological function of the
organism and its components, has import on assessing whether
that intervention is considered right or wrong [22].
Although it is doubtful, for example, whether human functions
could ever arise in an embryonic mouse host, the entire prenatal
development time of which is a mere fifteenth of a human being’s,
Karpowicz and co-authors have proposed some limits to chimeric
experiments [22]. They suggested that the number of human cells
transferred should be limited, that the choice of host animals for
early blastocyst chimeras be deliberate, and that dissociation of
human cells, rather than postanatomical tissue transplants should
be applied for later embryonic chimeras. According to these sug-
gestions, fewer human cells, in principle, would reduce the degree
of ‘humanization’ in early chimeric experiments, as the host cells
would outnumber the human cells. To ensure any potential psy-
chological impact of neuronal alterations in chimeric organisms,
the use of non-human animals that are closely functionally or
 morphologically related to humans should be only attempted
 during later embryonic development, when the host’s unique
 neural networks have already formed to the point that human
incursion could not occur. Dissociation of human stem cell
xenografts into early or later embryonic hosts could be regulated
if necessary, to guard against the possibility of human character-
istic pattern formation and development [22].
The mixing of genes, human and animal cells or tissues from
humans with those of animals has been studied for many years. In
reality, techniques involving human-animal combinations have
been used in the laboratories for decades. For instance, the utiliza-
tion of animal cells (irradiated mouse fibroblasts) as carriers for
the culture of human keratinocytes has been common practice 
for decades by now. The transplantation of cultured human
 keratinocytes propagated on animal cell feeder layers has also
been published to be life saving in extensively burned patients
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[41–46]. Serum-free culture techniques and utilization of bioma-
terials have been introduced to circumvent animal influences on
cultured human cells [43, 44, 46]. Suggestions that animal eggs
should, for example, be used to create hybrid human-animal
embryos have elicited some strong reactions in the international
news. Guidelines and regulations have to be discussed freely in
the scientific community and should be brought on their way with
the help of ethicists.
Gene therapy in cell science 
and tissue engineering
It is quite obvious that the potential market for gene-specific
 pharmaceuticals is huge. Hence, research in cellular and molecular
medicine involving alteration of the genome is one of the corner-
stones of scientific progress. Ethically, the idea of gene therapy is
to introduce or to alter genetic material to compensate for a genetic
mistake that causes disease. By doing so, it is hoped that one day
by means of gene therapy diseases can be treated or cured for
which up to now no other effective treatments are available.
However, many unique technical and ethical considerations
have been raised by this comparatively new form of treatment
[47]. Consecutively several levels of regulatory committees have
been established to review each gene therapy clinical trial prior to
its initiation in human subjects. Ethical considerations include the
decision which diseases and/or traits are eligible for gene therapy
research, how gene therapy can be safely tested and evaluated in
humans, which cell types should be used, what components are
necessary for informed consent.
Several ethicists have argued that genes and genetically modi-
fied organisms should be considered part of the common heritage
of all people. Other thinkers and advocates have raised equity
issues about the role of patents in impeding development and
access to beneficial technologies. The World Health Organization
has reminded member states that ‘justice demands equitable
access to genetic services’. WHO has also stated that ‘Genetic
services for the prevention, diagnosis and treatment of disease
should be available to all, without regard to ability to pay, and
should be provided first to those whose needs are greatest.’ [48]
While the fascination of genetic information has rapidly come
to be appreciated by societies at large, it is also narrowly perceived
that only analyses involving nucleic acids (i.e. DNA, RNA) yield
genetic information. The fact that superficially ‘non-genetic’ analy-
ses, e.g. of proteins, hormones, metabolites and even radiologic
imaging may, in certain situations, be equally informative as geno-
typing appears to have escaped many [49]. This may explain the
individual tendency to handle what is wrongly perceived to be
‘non-genetic’ medical information with much less care and atten-
tion to bioethics concerns than overtly ‘genetic’ information. Given
the relatively large corpus of medical information not derived from
DNA or RNA analysis, this issue is by far more complex and 
continues to challenge items of privacy in cell and tissue research
with regard to individual and epidemiological data acquired from
such research [50].
Although a considerable discussion about gene therapy has
been reported long before the first approved human gene therapy
trial in 1990 was initiated on severe combined immune deficiency
patients the debate remains controversial [26, 51–56].
Internationally, numerous policy statements on human
genetic intervention have been published, all of which support
the moral legitimacy of somatic-cell gene therapy for the cure of
disease. The debate over the ethical issues related to somatic-
cell gene therapy has evolved over a 10-year period [56]. When
lay perceptions about gene-based therapy are explored there are
differences in the perception in various countries and societies.
A survey in Iceland, following an intensive public debate on the
consequences of the Human Genome Project over the next 
40 years, revealed that the lay public was relatively optimistic
with regard to the future of drugs and gene-based therapy.
Reasons for this optimism were considered to be found in a
basic trust and belief in the welfare state and the health system
of this country. These results are not consistent with studies
carried out in other countries where the public appears to be
focused on the negative effects of genetic research and the
threats to privacy [55].
Since the hallmark of ethical medical research is informed
consent it has been considered to be important that voluntary
consent be imperative in this context. The dilemma can arise
when gene therapy may be the only possible treatment, or the
treatment of last resort, for some individuals. In such cases, it
becomes questionable whether the patient can truly be said to
make a voluntary  decision to participate in the trial. These criteria
do not apply when genetic alterations are performed in a strictly
experimental laboratory setting and when there is no application
to human beings [50].
Richter and Bacchetta [47] have proposed a three-dimensional
framework for the ethical debate of gene therapy where they added
the genomic type (nDNA versus mtDNA) as a third dimension to
be considered beside the paradigmatic dimensions of target cell
(somatic versus germ-line) and purpose (therapeutic versus
enhancement). According to their considerations somatic gene
therapy can be viewed today as generally accepted. They conclude
that many of the supposed ethical questions of somatic gene
 therapy today were not new at all, but should be considered as
rather well-known issues of research ethics.
Tissue banking for cellular and molecular
science and tissue engineering
Although tissue banking in some form or another has been
 practised for well over a century, it is only in the last decade that
tissue banking has come into the public limelight with the recent
surge of interest in the new life sciences, and in particular, in the
fields of human genetics and genomic research. Tissue banking as
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a means to provide material for medical research is by far not a
new phenomenon. The German pathologist Rudolf Virchow [58]
for instance initiated the first known repository in 1847. He even-
tually amassed more than 23,000 human tissue specimens. Ever
since that time a large number of (mainly pathology or dermatology)
departments in academic medical institutions and hospitals
around the world is housing temporary or permanent collections of
preserved human tissues and or organs. In his ground-breaking
book ‘Die Cellularpathologie in ihrer Begrundung auf physiologis-
che und pathologische Gewebelehre...’ (‘Cellular Pathology in its
foundation on physiological and pathological tissue science’) 
(see Fig. 1), published in 1858, he set a cornerstone of modern
medicine and biology based upon physiological and pathological
histology with his postulate: ‘omnis celula e(x) cellula’ (‘Every cell
is derived only from a preexisting cell’. He originated the idea that
each cell in each living organism, both plant and animal, originates
from another cell and that the origin of disease can only be located
in the cell.
Essentially, it has to be reminded that Rudolf Virchow, with his
book, changed abruptly the scientific thoughts and conceptions in
the whole field of medicine and biology at his time.
Presumably, for the father (or founder) of pathology the
(human) body is like a ‘cell state’ in which each cell acts as a 
‘citizen’! Accordingly, this could metaphorically be called a ‘cell
democracy’. Virchow’s assemblage of tissues was an invaluable
tool for his research efforts.
There is no doubt that tissue samples in such collections that
were originally sampled for patient-related diagnostic procedures
now serve as an invaluable tool and resource for research purposes.
Concurrent with the enormous advancement of genomic research
it now seems very realistic that large-scale genotyping and the
investigation of the human genome with new techniques for high
capacity molecular characterization will yield a plethora of discov-
eries to both academia and industry. For instance, vital epidemio-
logical information about the pattern and incidence of occurrence
of various forms of diseases such as cancers has been (and
 continues to be) gained from human tissue research, and through
the analysis of such information, important discoveries about the
prevention, control and treatment of such diseases have been
made for the benefit of humankind [49].
Currently, there are no clear guidelines as to whether referring
or sending physicians have a right to demand the return of these
tissue samples. At the Singapore University, it has been suggested
that if non-institutional collections have to be made for any reason
(for example, collections of a specific kind of tissue pursuant to a
specific research project), such collections should only be
 assembled on the understanding that the human tissues collected
will eventually be consolidated with the larger collections of
 institutions (for example, by a hospital, a university or a research
institution) [49]. Institutional human tissue holdings should then
set up a current database of all human tissue holdings within that
institution. Such a database could be part of the institution’s data-
base of research projects, with information fields such as the
research area, disease, human tissue collected, where they are
stored within the institution, and the units and persons responsi-
ble for these human tissues. This is recommended because the
size of holdings is also an important benefit of consolidation: a
large-scale collection is believed to be more useful (particularly for
population studies) than a small and limited collection [49].
Ethically one can discern the collection of tissues or cells in
such banks into therapeutic/diagnostic tissue collections (samples
are kept only as a part of the medical records of patients and are
not applied towards research purposes) from the collection of
cells and tissue for research purposes. If the latter aspect is
 pursued in combination with diagnostic/therapeutic sampling,
adequate informed consent of the individual has to be obtained to
fulfil ethical requirements.
There has also been a parallel trend towards the establishment
of collections of human tissue in which the biological material
remains viable or potentially viable, at least in some respects, at
the cellular level. For instance, human tissue samples may be
flash-frozen, and/or living cell lines may be propagated on culture
media. This greatly increases the value of the samples for many
lines of research. Institutions such as the Singapore University
have taken the view that such purposed-assembled research
banks are to be encouraged, provided that all appropriate ethical
and legal considerations and concerns are appropriately met and
addressed, as they promote and enhance research, which offers
the promise of immense benefit in the future for humankind.
At the present time, there does not appear to be any uniform
approach to the governance and regulation of tissue banking
internationally. The Draft Discussion Document entitled Data
Storage and DNA Banking for Biomedical Research: Informed
Consent, Confidentiality, Quality Issues, Ownership, Return of
Benefits: A Professional Perspective issued by the Public and
Professional Policy Committee of the European Society of Human
Genetics as part of the EUROGAPP Project 1999–2000 offers an
illuminating survey of the gamut of existing opinions, legislation,
guidelines and other policy statements applied in or issued by EC
institutions, 18 European countries, the United States, and inter-
national organisations. Except in the case of the United States,
© 2008 The Authors
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Fig. 1 Photograph of infamous mouse with the human ear, depicting new
tissue-engineered cartilage generated in the shape of a human ear (C. A.
Vacanti. Ref. [1]).
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and possibly France, the majority of the jurisdictions surveyed are
notable more for the absence of specific agreed national guide-
lines or legislation than by the presence of such in relation to
storage of data derived from human tissue research and DNA
banking. One of the prerequisites from an ethical standpoint
seems to be that informed  consent should be obtained from any
potential donor of tissue or cell samples if there is any possibility
that donated tissue samples may in the future be made available
for commercial research with consequent financial benefit or gain
to third parties, then this  possibility must be made clear to
donors at the very outset even if the arrangement is to be that the
donors completely renounce their rights to any share of these
gains or benefits [49].
It can be also recommended that all research using human 
tissue samples should be approved by an appropriately con-
stituted research ethics committee or institutional review board.
In addition it should be common sense that researchers and all
those involved in the conduct of tissue banking have an obligation
to protect the confidentiality of the personal information of donors
entrusted to them, as well as the privacy of donors.
Legal and intellectual property 
considerations
Ex vivo tissue-engineered products have been around for the last
decade and are now increasingly entering clinical trials.
Autonomous decision making on their participation is believed to
be a prerequisite to allow prospective recipients of such tissue-
engineered products to decide upon any legal and ethical aspects
of such procedures. Compared to current practice in cell and tissue
transplantation there are new elements in the transplantation of ex
vivo tissue-engineered materials. These can be summarized into
(i ) the source and manipulation of the cells in the product, 
(ii ) the implantation of the product and (iii ) the additional risks
and benefits due to the construction of the product and its activity
in the body [9].
Thorough informed consent should be reached that takes the
specific aspects of tissue engineering into account. The delicate
nature of specific cell types and the various complexities of the 
tissue engineering process as well as its implications have to be
made clear. When a clinical trial is conducted with such tissue-
engineered products, any crucial issue, potential benefits and 
specific and general risks have to be made clear to the potential
recipient according to his capacity to understand the whole proce-
dure. The assistance of informed third parties has been proposed
to help participants in their decision-making processes [9].
Attempts of governmental regulatory boards such as the
European Commission to develop a directive to regulate all tissue-
engineered products in a comprehensive yet flexible framework
have been criticized from an ethical viewpoint [10]. It has been
argued that there are shortcomings to such proposals because of
disjunctures at various regulatory levels and because responsibil-
ities of several authorities have not been clearly established.
The appropriateness of patenting gene patterns, DNA
sequences and life forms has been a source of considerable con-
troversy. Generally before the advent of modern genomic research,
until 1980, life forms were considered to be ‘products of nature’
and ineligible for patent protection. In the 20 years since the first
biotechnology patents were granted, various critics have claimed
that the patenting of living things promotes a reductionist concep-
tion of life that removes any distinction between living and non-liv-
ing things. Some scientists and lawyers have questioned whether
these patents promote the future biomedical research [48, 49].
Fig. 2 With his publication of ‘Die Cellularpathologie in ihrer
Begruendung auf physiologische und pathologische Gewebelehre’ in
1859, Rudolf Virchow (1821–1902) originated the idea that each cell in
each living organism, both plant and animal, originates from another cell
and that the origin of disease can only be located in the cell. This book is




There is no doubt that numerous advancements of science have
transformed our lives in a way that would have been unthinkable of
just a century ago. While many aspects seem to be common sense
today, the field of embryonic or adult stem cell research raises a lot
of severe ethical questions. It is unclear at the moment if results of
stem cell research will have a similar effect than other scientific
achievements, but the promise is so great that it seems wise to
consider seriously how best to further such research in a manner
that is sensitive to ethical objections. Public perceptions and con-
versations and ethical objections about research and use of human
stem cells should be recognized and embedded into an ongoing
dialogue. The authors want to bring to the public awareness that
not always a clear-cut separation of the ethical problems and the
pragmatic approach to biomedical decisions – including the field of
molecular and cellular medical interventions – can be easily made.
Similar to others [49] we take the view that the vast majority of
scientists and researchers in cellular and molecular medicine are
responsible and are acutely aware of potential ethical concerns in
the work that they do, and in that which they may propose to carry
out. Scientists do not presume to know all the answers and rami-
fications of basic research in human cells. Most wish to do what
is ethically right. Indeed, many may be inhibited from participating
in some areas of research (which may in fact be entirely accept-
able to the community, and in the public interest) by the lack of
clear ethical direction or agreement on a given point, or by uncer-
tainty generated by controversy in related areas.
Therefore, it is important to promote continued dialogue
among all segments of society concerning the implications of cel-
lular and molecular research. Ongoing educational processes fos-
tered by public institutions and supported by researchers that
informs such public dialogue seems desirable. As stated by the
AAAS it should be recognized that science does not exist in isola-
tion from the larger community that feels its effects, whether per-
ceived as good or bad. The work of scientists is, and should be,
conditioned and directed by consideration of broader human val-
ues. This means that the development of public policy, especially
where highly controversial matters are involved, must take all
interested sectors of the public into account. It is only through
broad-based participation that the values of all stakeholders in the
research enterprise can be carefully considered and weighed [21].
© 2008 The Authors
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